MLDA
Ways to Support   |   Be a Friend   |   Be a Member   |   Feedback & Enquiry   |   Contact Us


  Find us on:    


Sign Up for E-Newsletter  

 
MLDA
   Home » Patients » Clinical Trials » 
  Patients
  Patients Stories
  Patient Communities
  Clinical Trials
  Memorials
 
 
 
 
Ardi Izzuddin

Ardi has received his first trial drug from US, Ultragenyx Pharmaceutical Company. This drug is first in Asia! It is worth waiting, praying and hoping that one day he will be like before, playing, talking and running. We also thanked KEMENTERIAN KESIHATAN MALAYSIA, the doctors and nurses that help Ardi along the process. It is a bless for Ardi's parents, Zabidi Ali.
» Read more..
 
 
BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced an update on the GALNS Phase 1/2 extension study (MOR-100) in which patients have continued treatment on an ongoing basis.
» Read more..
 
 
BioMarin Reports Positive Results for Phase I/II Trial for BMN 110 for MPS IVA

Novato, Calif, April 29, 2010 – BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive results for the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome.
» Read more..
 


 
 
| | | |
© Copyright Malaysia Lysosomal Diseases Association (Pertubuhan Penyakit Lisosomal Malaysia) 2011    All rights reserved.
Registration No: 2621-NSE
1520, TAMAN BUKIT KAYA, 70200 SEREMBAN, NEGERI SEMBILAN, MALAYSIA.
Email:       Telephone: 019-6899620